By
WilD on
November 26, 2011
Welcome back to our Saturday diabetes advice column, Ask D’Mine, hosted by veteran type 1, diabetes author and community educator Wil Dubois — where myths get busted and unseemly topics sometimes see the light of day. Hey, where else ya gonna turn?
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
First things first this week:
Exercising over 250 mg/dL CORRECTION:
Last week we talked about how it’s generally considered unsafe to start…
Read more »
Lack of access to diabetes supplies and education is a serious issue that we often talk about in regards to developing countries. But the fact of the matter is that it’s also a huge problem here in the U.S. This month’s DSMA (Diabetes Social Media) carnival topic aims to tackle the issue with this question:
Let’s discuss the lack of diabetes education, supplies and insulin for PWDs living here and in other countries. What can…
Read more »
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »